Clinical Scorecard: Beyond Morphology and IHC

At a Glance

Key Highlights

• Molecular testing can uncover actionable biomarkers in approximately 30% of CUP cases, not just 21.4%.

Guideline-Based Recommendations

Diagnosis

• Utilize molecular testing when morphology and IHC are inconclusive.
• Consider clinical context and history of prior malignancy.
• Engage in multidisciplinary discussions for diagnosis.

Management

Monitoring & Follow-up

Risks

Patient & Prescribing Data

Approximately 21.4% of CUP patients may become eligible for targeted therapy based on genomic findings, contextualized with molecular testing.

Clinical Best Practices

• Engage in shared decision-making with patients regarding molecular testing.
• Utilize large-panel targeted sequencing for better differentiation of tumor types.
• Consider timing of molecular testing in relation to treatment decisions.

References

• CAP Report on Molecular Testing